LPL Financial’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

LPL Financial’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,667	Closed	-$608K	–	4729
2023 Q1	$608K	Buy	5,667 +201	+4%	+$23.1K	﹤0.01%	3165
2022 Q4	$601K	Buy	5,466 +449	+9%	+$29.1K	﹤0.01%	3084
2022 Q3	$296K	Buy	+5,017	New	+$230K	﹤0.01%	3606

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

LPL Financial's RXDX Position: Q2 2023 in Review

LPL Financial sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 5,667 shares — an estimated $608K sold.

LPL Financial first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $608K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

LPL Financial reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
LPL Financial sold 5,667 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $608K.
LPL Financial first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
LPL Financial's Prometheus Biosciences, Inc. Common Stock position peaked at $608K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on LPL Financial's 13F filing for Q2 2023, filed 31 Jul 2023.